Congenital Adrenal Hyperplasia: The 21-Hydroxylase Block

What CAH is and why it matters clinically

Congenital adrenal hyperplasia is not one disease but a family of autosomal recessive enzyme defects in the adrenal steroidogenic pathway. The unifying theme: an enzyme block impairs cortisol synthesis, and the resulting loss of negative feedback drives relentless ACTH secretion from the pituitary. Chronic ACTH stimulation causes the adrenal cortex to enlarge — the literal hyperplasia in the name — and pushes precursors that accumulate above the block down alternative pathways.

• 21-hydroxylase deficiency (gene CYP21A2) causes ~95% of cases.
• Less common blocks: 11β-hydroxylase (hypertension + androgen excess) and 17α-hydroxylase (hypertension + low androgens).

It matters because the classic salt-wasting form is a genuine neonatal emergency: undiagnosed infants present in circulatory collapse. It is also the most common cause of ambiguous genitalia in a 46,XX newborn, and the non-classic form is a frequently missed cause of hyperandrogenism in adolescent and adult women that masquerades as PCOS.

The mechanism: where the 21-hydroxylase block bites

Adrenal steroidogenesis is a branching pathway. Cholesterol is converted to pregnenolone, then progesterone, then the three end-products depend on which enzymes act. 21-hydroxylase (CYP21A2) is required for two of the three arms:

• It converts progesterone → 11-deoxycorticosterone (the mineralocorticoid arm → aldosterone).
• It converts 17-hydroxyprogesterone → 11-deoxycortisol (the glucocorticoid arm → cortisol).

When the enzyme fails, both aldosterone and cortisol fall. Crucially, the enzyme is not needed for the androgen arm. So the substrate that piles up above the block — 17-hydroxyprogesterone (17-OHP) — is shunted into androstenedione and testosterone.

The result is a triple hit: (1) cortisol deficiency, which unleashes ACTH and drives adrenal growth; (2) aldosterone deficiency, causing renal salt loss, hyponatremia, and hyperkalemia; and (3) androgen excess, causing virilization. The severity tracks tightly with residual enzyme activity — near-zero activity gives the salt-wasting phenotype, partial activity gives milder forms.

Clinical presentation and classic signs

Presentation depends on age, karyotype, and enzyme severity:

• Neonatal salt-wasting crisis (classic): Days 7-14 of life, the infant develops poor feeding, vomiting, lethargy, failure to thrive, and dehydration progressing to shock. Labs show the hallmark hyponatremia, hyperkalemia, and hypoglycemia with metabolic acidosis. This can be fatal if mistaken for pyloric stenosis or sepsis.
• Virilization of 46,XX females: Excess prenatal androgens cause ambiguous genitalia — clitoromegaly, labial fusion, a common urogenital sinus — quantified by the Prader stages (I-V). Internal Müllerian structures (uterus, ovaries) are normal because there is no AMH excess.
• 46,XY males: Genitalia appear normal at birth, so salt-wasting boys can be missed until crisis — one reason newborn screening is vital.
• Non-classic: Presents later with premature pubarche, accelerated growth then early epiphyseal closure and short adult stature, hirsutism, acne, menstrual irregularity, and subfertility.

Diagnosis: the specific tests and cutoffs

The disease is defined biochemically by the substrate that accumulates above the block.

• 17-hydroxyprogesterone (17-OHP) is the key analyte. It is markedly elevated — often >1,000-10,000 ng/dL (30-300 nmol/L) in classic disease versus a normal baseline under ~100 ng/dL. It is the marker used in newborn screening (heel-stick, days 1-3).
• ACTH (cosyntropin) stimulation test confirms borderline or non-classic cases: a stimulated 17-OHP >1,000-1,500 ng/dL (>30 nmol/L) is diagnostic; values in the 200-1,000 range suggest non-classic disease or carrier status.
• Electrolytes: hyponatremia + hyperkalemia in salt-wasters; plasma renin is high (with low/inappropriate aldosterone) confirming mineralocorticoid deficiency.
• Karyotype and pelvic ultrasound for ambiguous genitalia — a 46,XX with a normal uterus and elevated 17-OHP is virtually diagnostic.
• CYP21A2 genotyping confirms the diagnosis, guides genetic counseling, and enables prenatal diagnosis.

Pitfall: screening 17-OHP can be falsely elevated in premature/stressed neonates; confirm with a repeat or ACTH test.

Management: why each treatment works

Therapy targets the two arms of the deficiency and simultaneously suppresses the androgen excess.

• Glucocorticoid replacement (hydrocortisone in children): Replacing cortisol does two jobs — it treats the deficiency and restores negative feedback on the pituitary, lowering ACTH. Less ACTH means less drive to the androgen pathway, so virilization is controlled. In children, hydrocortisone is preferred (short-acting, least growth suppression); prednisolone or dexamethasone are options in adults.
• Mineralocorticoid replacement (fludrocortisone): Replaces aldosterone to retain sodium, excrete potassium, and normalize volume/renin. Infants also need sodium chloride supplementation.
• Stress dosing: Because these patients cannot mount a cortisol response, glucocorticoid doses must be tripled during illness, surgery, or trauma, with IV hydrocortisone for crisis — the do-not-miss rule that prevents fatal adrenal crisis.
• Acute salt-wasting crisis: IV normal saline + dextrose, IV hydrocortisone, and correction of hyperkalemia.

Surgical genitoplasty and psychosocial support are individualized; emerging therapies include the CRF1 antagonist crinecerfont, which lowers ACTH-driven androgens and permits lower steroid doses.

Distinctions, mimics, and pitfalls

The differential shifts with the presentation:

• Salt-wasting neonate: Do not anchor on sepsis or pyloric stenosis. Pyloric stenosis gives a hypochloremic, hypokalemic metabolic alkalosis — the opposite electrolyte picture from CAH's hyponatremia + hyperkalemia + acidosis. Check electrolytes early.
• Other CAH enzymes: 11β-hydroxylase deficiency also virilizes but causes hypertension and hypokalemia (deoxycorticosterone accumulates). 17α-hydroxylase deficiency causes hypertension with low androgens (no virilization). If a virilized patient is hypertensive, think 11β, not 21.
• Non-classic CAH vs PCOS: Both cause hirsutism and oligomenorrhea; a screening morning 17-OHP distinguishes them and should be checked in hyperandrogenic women.
• Overtreatment pitfalls: Excess glucocorticoid causes iatrogenic Cushing's and growth suppression; excess fludrocortisone causes hypertension. Titrate to renin, 17-OHP, androstenedione, and growth velocity/bone age — not to 17-OHP alone.

Forms of 21-hydroxylase deficiency: from complete enzyme loss to partial activity

Feature	Classic salt-wasting	Classic simple-virilizing	Non-classic (late-onset)
Residual enzyme activity	0% (near-complete loss)	~1-2%	20-50%
Aldosterone / salt-wasting	Yes — life-threatening crisis	No (borderline preserved)	No
Cortisol deficiency	Yes	Yes	Minimal / subclinical
Genital ambiguity at birth	46,XX virilized	46,XX virilized	Normal at birth
Typical presentation	Neonatal crisis, days 1-2 wk	Virilization, early puberty	Hirsutism, acne, oligomenorrhea, infertility
Approx. frequency	~75% of classic cases	~25% of classic cases	Up to 1:200-1:1000 (much more common)